ArticleBMC emergency medicine2025
Prevalence, symptoms, risk factors and impact of sepsis-associated encephalopathy in emergency department patients: a case-control study.
Article in BMC emergency medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- miR-125b Attenuates Sepsis-Induced Hippocampal Mitochondrial Fission and Cognitive Impairment via the ROS/p53 Pathway.Molecular neurobiology · 2026Article
- Effects of fullerenol CExperimental and therapeutic medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGlobal sepsis statistics exhibit a morbidity of 48.9 million with 11.0 million sepsis-related deaths. Despite ongoing research and guideline updates it remains a serious epidemiological concern. Sepsis-associated encephalopathy (SAE) is one of the more dangerous sepsis complications, due to its potential to cause permanent central nervous system damage. This study aimed to examine the prevalence, symptoms, risk factors, and impact of SAE on disease course in emergency department patients.
methodsThis retrospective study was performed in an emergency department of a university hospital. We analyzed medical records of patients from January 2021 till the end of December 2022. All admitted patients diagnosed with sepsis according to the sepsis-3 consensus were included. Patients with disseminated neoplastic disease, chronic neurological conditions with impact on cognitive and communicative functions, and pediatric patients were excluded. Based on laboratory tests and clinical symptoms of encephalopathy, the patients were divided into SAE and non-SAE groups. Chi-square test was used to assess results’ significance.
resultsA total of 443 patients with sepsis were included in the study, of whom 240 presented with SAE. The most common SAE symptoms include general consciousness deterioration, disorientation, and somnolence. Patients with SAE were older and had heart failure more frequently. Mortality rate in the SAE group was significantly higher and equaled 45.42% vs 7.88% in the non-SAE group (p-value < 0.001). The most commonly identified pathogens in the blood cultures were Escherichia coli and Staphylococcus aureus.
conclusionThe study showed that SAE is a common sepsis complication (54% prevalence) that significantly increases in-hospital mortality. Older patients with chronic neurological disorders and heart failure are particularly vulnerable. The SOFA, NEWS, and Glasgow Coma Scale scores have proven to be reliable predictors of SAE occurrence.
trial registrationThis study is not a clinical trial.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.